Zydus and Lupin Forge Strategic Partnership to Develop Semaglutide for Diabetes Treatment
Indian pharmaceutical companies Zydus Lifesciences and Lupin Limited have announced a strategic collaboration to develop and commercialize Semaglutide, a widely recognized therapy for managing type 2 diabetes. The partnership highlights a growing trend among domestic drug manufacturers to collaborate on high-value treatments in rapidly expanding therapeutic markets. With diabetes cases rising globally and particularly in India, the initiative could strengthen the companies’ presence in the lucrative metabolic disease segment.
Tags